Drug Evaluation Committee Slide presentation "From the Pharmaceutical Industry - "How do you want us to utilize? Thoughts on various materials" (November 1, 2025, 19th Annual Meeting of the Japanese Society of Pharmacy)
Pharmacovigilance Subcommittee
December, 2025
This document consists of lecture slides at the following symposium.
The 19th Annual Meeting of the Japanese Society of Pharmacognosy
Symposium 1: It's too late to ask! Collection and provision of drug information
Lecture slides (Symposium 1 of the 19th Annual Meeting of the Japanese Society of Pharmacognosy)
With the diversification of drug discovery modalities such as cell therapy and gene therapy, the provision of drug information has become increasingly important for appropriate treatment selection and patient safety. Therefore, in addition to "RMP materials" based on drug risk management plans, pharmaceutical companies are creating and providing various materials and applications tailored to the characteristics of their drugs, such as side effect alerts, formulation usage instructions, and symptom management tools.
In light of the diversification of drug types, materials and tools, and patient needs and environments, there is an urgent need for medical professionals to collect up-to-date and accurate information and provide information tailored to patients, as well as to establish an environment in which patients themselves can access appropriate information. To this end, it is important to strengthen cooperation among related stakeholders such as government, medical professionals, and companies. In this symposium, we discussed together approaches to create an environment for the appropriate use of necessary information and a system that enables patients themselves to use drug information.
Deliverables of the Drug Evaluation Committee Return to list of all deliverables